We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Amarin (AMRN - Free Report) closed at $17.67, marking a -1.83% move from the previous day. This change lagged the S&P 500's daily gain of 1.09%. Elsewhere, the Dow gained 1.13%, while the tech-heavy Nasdaq added 1.51%.
Heading into today, shares of the biopharmaceutical company had lost 20.49% over the past month, lagging the Medical sector's gain of 4.8% and the S&P 500's gain of 1.92% in that time.
Investors will be hoping for strength from AMRN as it approaches its next earnings release, which is expected to be February 26, 2019. On that day, AMRN is projected to report earnings of -$0.08 per share, which would represent no growth from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $66.47 million, up 23.38% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.33 per share and revenue of $218.37 million, which would represent changes of -32% and +20.57%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for AMRN. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 13.77% higher. AMRN is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Amarin (AMRN - Free Report) closed at $17.67, marking a -1.83% move from the previous day. This change lagged the S&P 500's daily gain of 1.09%. Elsewhere, the Dow gained 1.13%, while the tech-heavy Nasdaq added 1.51%.
Heading into today, shares of the biopharmaceutical company had lost 20.49% over the past month, lagging the Medical sector's gain of 4.8% and the S&P 500's gain of 1.92% in that time.
Investors will be hoping for strength from AMRN as it approaches its next earnings release, which is expected to be February 26, 2019. On that day, AMRN is projected to report earnings of -$0.08 per share, which would represent no growth from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $66.47 million, up 23.38% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.33 per share and revenue of $218.37 million, which would represent changes of -32% and +20.57%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for AMRN. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 13.77% higher. AMRN is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.